Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 152


Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.

Cunningham EB, Harjarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, Luciani F, Teutsch S, Dolan K, Lloyd AR, Grebely J; HITS-p investigators..

J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701. [Epub ahead of print]


Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.

Grebely J, Swan T, Hickman M, Bruneau J, Bruggmann P, Dalgard O, Litwin A, Backmund M, Dore GJ; International Network for Hepatitis in Substance Users..

J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054-5. doi: 10.1016/j.jhep.2016.12.028. [Epub ahead of print] No abstract available.


Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.

Eltahla AA, Leung P, Pirozyan MR, Rodrigo C, Grebely J, Applegate T, Maher L, Luciani F, Lloyd AR, Bull RA.

Sci Rep. 2017 Jan 31;7:41719. doi: 10.1038/srep41719.


Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA; InC(3) Study Group..

Infect Genet Evol. 2017 Apr;49:88-96. doi: 10.1016/j.meegid.2017.01.006. Epub 2017 Jan 5.


HCV reinfection incidence among individuals treated for recent infection.

Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV.

J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666. [Epub ahead of print]


Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.

Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC)..

CMAJ Open. 2016 Oct 14;4(4):E605-E614. doi: 10.9778/cmajo.20160008. eCollection 2016 Oct 14.


A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.

Bartlett SR, Wertheim JO, Bull RA, Matthews GV, Lamoury FM, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J.

J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652. [Epub ahead of print]


The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C.

van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland SA, Marshall A, Saeed S, Wilson J, Klein MB, Sagan SM.

Can J Gastroenterol Hepatol. 2016;2016:7603526. Epub 2016 Oct 24.


The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.

Tsui JI, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore GJ, Lauer G, Lloyd AR, Page K.

Drug Alcohol Depend. 2016 Dec 1;169:156-162. doi: 10.1016/j.drugalcdep.2016.10.024. Epub 2016 Oct 26.


Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.

Rodrigo C, Eltahla AA, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Lloyd AR; InC3 Collaborative..

J Viral Hepat. 2017 Jan;24(1):43-52. doi: 10.1111/jvh.12616. Epub 2016 Nov 3.


Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group..

Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.


Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.

Martinello M, Gane E, Hellard M, Sasadeusz J, Shaw D, Petoumenos K, Applegate T, Grebely J, Maire L, Marks P, Dore GJ, Matthews GV.

Hepatology. 2016 Dec;64(6):1911-1921. doi: 10.1002/hep.28844. Epub 2016 Oct 27.


The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).

Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall M, Krajden M.

EBioMedicine. 2016 Oct;12:189-195. doi: 10.1016/j.ebiom.2016.08.035. Epub 2016 Aug 25.


Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia.

Fortier E, Alavi M, Bruneau J, Micallef M, Perram J, Sockalingam S, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Grebely J; ETHOS Study Group..

J Addict Med. 2017 Jan/Feb;11(1):10-18. doi: 10.1097/ADM.0000000000000261.


Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.

Alavi M, Law MG, Grebely J, Amin J, Hajarizadeh B, George J, Dore GJ.

J Hepatol. 2016 Nov;65(5):879-887. doi: 10.1016/j.jhep.2016.06.025. Epub 2016 Jul 8.


Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.

Eltahla AA, Rodrigo C, Betz-Stablein B, Grebely J, Applegate T, Luciani F, Schinkel J, Dore GJ, Page K, Bruneau J, Morris MD, Cox AL, Kim AY, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd AR, Bull RA; InC3 Study Group..

J Viral Hepat. 2017 Jan;24(1):37-42. doi: 10.1111/jvh.12615. Epub 2016 Sep 25.


MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M; International Liver Disease Genetics Consortium..

Nat Commun. 2016 Sep 15;7:12757. doi: 10.1038/ncomms12757.


Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia.

Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group..

J Infect Dis. 2016 Nov 1;214(9):1383-1389. Epub 2016 Aug 28.


Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ.

J Hepatol. 2016 Dec;65(6):1086-1093. doi: 10.1016/j.jhep.2016.08.010. Epub 2016 Aug 26.


Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ.

Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. Epub 2016 Aug 23.


Supplemental Content

Loading ...
Support Center